osteoporosis pipeline insight

DelveInsight’s, “Osteoporosis - Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Osteoporosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Osteoporosis: Understanding

Osteoporosis: Overview

Osteoporosis is a bone disease that develops when bone mineral density and bone mass decreases, or when the quality or structure of bone changes. This can lead to a decrease in bone strength that can increase the risk of fractures (broken bones). Osteoporosis is a “silent” disease because a person typically do not have symptoms, and may not even know that they have the disease until they break a bone. Osteoporosis is the major cause of fractures in postmenopausal women and in older men. Fractures can occur in any bone but happen most often in bones of the hip, vertebrae in the spine, and wrist. Osteoporosis affects women and men of all races and ethnic groups. Osteoporosis can occur at any age, although the risk for developing the disease increases as one gets older. Osteoporosis is most common in non-Hispanic white women and Asian women. Among men, osteoporosis is more common in non-Hispanic whites. Osteoporosis is called a “silent” disease” because there are typically no symptoms until a bone is broken or one or more vertebrae collapse (fracture). Symptoms of vertebral fracture include severe back pain, loss of height, or spine malformations such as a stooped or hunched posture (kyphosis).Bones affected by osteoporosis may become so fragile that fractures occur spontaneously or as the result of: Minor falls, such as a fall from standing height that would not normally cause a break in a healthy bone. Normal stresses such as bending, lifting, or even coughing. Osteoporosis occurs when too much bone mass is lost and changes occur in the structure of bone tissue. Certain risk factors may lead to the development of osteoporosis or can increase the likelihood that will develop the disease. Many people with osteoporosis have several risk factors, but others who develop osteoporosis may not have any specific risk factors. There are no clear physical signs of osteoporosis and it may not cause any problems for some time. If doctor thinks the patient might have osteoporosis, they may suggest to have a DEXA (dual energy x-ray absorptiometry) scan to measure the density of bones. The U.S. Preventive Services Task Force recommends screening for: Women over age 65, women of any age who have factors that increase the chance of developing osteoporosis. The goals for treating osteoporosis are to slow or stop bone loss and to prevent fractures. People who develop osteoporosis from another condition should work with their health care provider to identify and treat the underlying cause.

"Osteoporosis- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteoporosis pipeline landscape is provided which includes the disease overview and Osteoporosis treatment guidelines. The assessment part of the report embraces, in depth Osteoporosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteoporosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Osteoporosis R&D. The therapies under development are focused on novel approaches to treat/improve Osteoporosis.

Osteoporosis Emerging Drugs Chapters

This segment of the Osteoporosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Osteoporosis Emerging Drugs

AVT03: Alvotech

AVT03 is a human monoclonal antibody and a biosimilar candidate to Prolia and Xgeva (denosumab). Denosumab targets and binds with high affinity and specificity to the RANK ligand membrane protein, preventing the RANK ligand/RANK interaction from occurring, resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer-induced bone destruction. AVT03 is an investigational product and has not received regulatory approval in any country. Currently, the drug is in Phase III stage of its development for the treatment of osteoporosis.

 

TST002: Transcenta Holding

TST002 (Blosozumab) is a humanized anti-sclerostin monoclonal antibody as a drug candidate for osteoporosis and other bone loss diseases. It has a dual effect possessing both anabolic and anti-resorptive effects, which stimulates bone formation and inhibits bone absorption, resulting in fast increase in bone mineral density and bone strength. Blocking sclerostin activity in human treated with anti-sclerostin antibody or with naturally occurring genetic deletion has been shown to be an effective approach in increasing bone mineral density (BMD) and reducing bone fracture.  Currently, the drug is in Phase II stage of its clinical trial for the treatment of osteoporosis.

 

Denosumab biosimilar: GlycoNex

GlycoNex, a Taiwanese biotech company, is developing a denosumab biosimilar called SPD8 for the treatment of osteoporosis. Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor kappa-B ligand (RANKL), a key regulator of osteoclast formation, function and survival. By blocking RANKL, denosumab reduces bone resorption and increases bone mineral density. GlycoNex recently reported positive results from a Phase I clinical trial of SPD8, which met its primary endpoint of pharmacokinetic equivalence to the reference product. Currently, the drug is in Phase II stage of its clinical trial for the treatment of osteoporosis.

Further product details are provided in the report……..

Osteoporosis: Therapeutic Assessment

This segment of the report provides insights about the different Osteoporosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Osteoporosis

There are approx. 30+ key companies which are developing the therapies for Osteoporosis. The companies which have their Osteoporosis drug candidates in the most advanced stage, i.e. Phase III include, Alvotech.

Phases

DelveInsight’s report covers around 35+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Osteoporosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Osteoporosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteoporosis drugs.

Explore the key factors, trends, innovations, and developments driving the market growth, at: Osteoporosis Market

Osteoporosis Report Insights

• Osteoporosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Osteoporosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Osteoporosis drugs?
• How many Osteoporosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteoporosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Osteoporosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Osteoporosis and their status?
• What are the key designations that have been granted to the emerging drugs?